Immunoregulatory role of TNFα in inflammatory kidney diseases

Kidney International

Volumn 76, Issue 3, 2009, Pages 262-276

  Ernandez, Thomas ^a   Mayadas, Tanya ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Autoimmunity; Glomerulonephritis; Kidney inflammation; TNF receptors; TNF ; Vasculitis

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; NEUTROPHIL CYTOPLASMIC ANTIBODY; PENTOXIFYLLINE; RECOMBINANT TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULAR CELL ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA;

ACUTE KIDNEY TUBULE NECROSIS; ALLERGIC ENCEPHALOMYELITIS; ANGIOGENESIS; APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELLULAR IMMUNITY; DELAYED HYPERSENSITIVITY; DNA POLYMORPHISM; HUMAN; IMMUNE COMPLEX NEPHRITIS; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOREGULATION; KIDNEY ALLOGRAFT REJECTION; KIDNEY DISEASE; KIDNEY INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTIC INFILTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS; VASCULITIS NEPHRITIS; WEGENER GRANULOMATOSIS; ANIMAL; DRUG ANTAGONISM; IMMUNOLOGY; NEPHRITIS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; NEPHRITIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67651119922     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.142     Document Type: Review

References (222)

1. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992; 10: 411-452.
2. Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev 2003; 14: 185-191.
3. Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005; 115: 1-20.
4. Carswell EA, Old LJ, Kassel RL et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72: 3666-3670.
5. Old LJ. Tumor necrosis factor (TNF). Science 1985; 230: 630-632.
6. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-1602.
7. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006; 355: 704-712.
8. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-1405.
9. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022.
10. Mease PJ, Goffe BS, Metz J et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-390.
11. Ogilvie AL, Antoni C, Dechant C et al. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001; 144: 587-589.
12. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-1193.
13. Gorman JD, Sack KE, Davis Jr JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346: 1349-1356.
14. Charles PJ, Smeenk RJ, De Jong J et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000; 43: 2383-2390.
15. William BT. Serious adverse events associated with use of anti-TNFa drugs. In: Center for Drug and Evaluation and Research, FDA documentation. http://www.fda.gov/cder/present/DIA2004/ Tauber-files/frame.htm, 2004.
16. De Bandt M, Sibilia J, Le Loet X et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005; 7: R545-R551.
17. Shakoor N, Michalska M, Harris CA et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359: 579-580.
18. Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebocontrolled trial of monoclonal antibody to human tumor necrosis factoralpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24: 1431-1440.
19. Gallagher J, Fisher C, Sherman B et al. A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-alpha antibody afelimomab in patients with sepsis syndrome. Intensive Care Med 2001; 27: 1169-1178.
20. Panacek EA, Marshall JC, Albertson TE et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab0)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004; 32: 2173-2182.
21. Reinhart K, Wiegand-Lohnert C, Grimminger F et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996; 24: 733-742.
22. Fisher Jr CJ, Agosti JM, Opal SM et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334: 1697-1702.
23. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999; 53: 457-465.
24. van Oosten BW, Barkhof F, Truyen L et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47: 1531-1534.
25. Kontoyiannis D, Kollias G. Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor. Eur J Immunol 2000; 30: 2038-2047.
26. Boissier MC, Chiocchia G, Bessis N et al. Biphasic effect of interferongamma in murine collagen-induced arthritis. Eur J Immunol 1995; 25: 1184-1190.
27. Joosten LA, Lubberts E, Helsen MM et al. Dual role of IL-12 in early and late stages of murine collagen type II arthritis. J Immunol 1997; 159: 4094-4102.
28. Gordon C, Wofsy D. Effects of recombinant murine tumor necrosis factor-alpha on immune function. J Immunol 1990; 144: 1753-1758.
29. Jacob CO, Lee SK, Strassmann G. Mutational analysis of TNF-alpha gene reveals a regulatory role for the 30-untranslated region in the genetic predisposition to lupus-like autoimmune disease. J Immunol 1996; 156: 3043-3050.
30. Jacob CO, McDevitt HO. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature 1988; 331: 356-358.
31. Bartolucci P, Ramanoelina J, Cohen P et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002; 41: 1126-1132.
32. Booth A, Harper L, Hammad T et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibodyassociated systemic vasculitis. J Am Soc Nephrol 2004; 15: 717-721.
33. Lamprecht P, Voswinkel J, Lilienthal T et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002; 41: 1303-1307.
34. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352: 351-361.
35. Feldmann M, Pusey CD. Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases. J Am Soc Nephrol 2006; 17: 1243-1252.
36. Aringer M, Smolen JS. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther 2008; 10: 202.
37. Aringer M, Steiner G, Graninger WB et al. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 274-279.
38. Dall'Era M, Wofsy D. A Randomized, Double-Blind, Placebo-Controlled, Phase II, Multi-Center Study for Treatment of Lupus Nephritis by Inhibition of Tumor Necrosis Factor-Alpha Using Etanercept (NCT00447265)http://www. clinicaltrials.gov, 2008.
39. Kriegler M, Perez C, DeFay K et al. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988; 53: 45-53.
40. Perez C, Albert I, DeFay K et al. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 1990; 63: 251-258.
41. Mueller C, Corazza N, Trachsel-Loseth S et al. Noncleavable transmembrane mouse tumor necrosis factor-alpha (TNFalpha) mediates effects distinct from those of wild-type TNFalpha in vitro and in vivo. J Biol Chem 1999; 274: 38112-38118.
42. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487-501.
43. Moss ML, Jin SL, Becherer JD et al. Structural features and biochemical properties of TNF-alpha converting enzyme (TACE). J Neuroimmunol1997; 72: 127-129.
44. Black RA, Rauch CT, Kozlosky CJ et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385: 729-733.
45. Al-Lamki RS, Wang J, Skepper JN et al. Expression of tumor necrosis factor receptors in normal kidney and rejecting renal transplants. Lab Invest 2001; 81: 1503-1515.
46. Niemir ZI, Ondracek M, Dworacki G et al. In situ upregulation of IL-10 reflects the activity of human glomerulonephritides. Am J Kidney Dis1998; 32: 80-92.
47. Aten J, Roos A, Claessen N et al. Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J Am Soc Nephrol 2000; 11: 1426-1438.
48. Baud L, Oudinet JP, Bens M et al. Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide. Kidney Int1989; 35: 1111-1118.
49. Noiri E, Kuwata S, Nosaka K et al. Tumor necrosis factor-alpha mRNA expression in lipopolysaccharide-stimulated rat kidney. Chronological analysis of localization. Am J Pathol 1994; 144: 1159-1166.
50. Gomez-Guerrero C, Lopez-Armada MJ, Gonzalez E et al. Soluble IgA and IgG aggregates are catabolized by cultured rat mesangial cells and induce production of TNF-alpha and IL-6, and proliferation. J Immunol1994; 153: 5247-5255.
51. Wuthrich RP, Glimcher LH, Yui MA et al. MHC class II, antigen presentation and tumor necrosis factor in renal tubular epithelial cells. Kidney Int 1990; 37: 783-792.
52. Jevnikar AM, Brennan DC, Singer GG et al. Stimulated kidney tubular epithelial cells express membrane associated and secreted TNF alpha. Kidney Int 1991; 40: 203-211.
53. Neale TJ, Ruger BM, Macaulay H et al. Tumor necrosis factor-alpha is expressed by glomerular visceral epithelial cells in human membranous nephropathy. Am J Pathol 1995; 146: 1444-1454.
54. Donnahoo KK, Meng X, Ao L et al. Differential cellular immunolocalization of renal tumour necrosis factor-alpha production during ischaemia versus endotoxaemia. Immunology 2001; 102: 53-58.
55. Misseri R, Meldrum DR, Dagher P et al. Unilateral ureteral obstruction induces renal tubular cell production of tumor necrosis factor-alpha independent of inflammatory cell infiltration. J Urol 2004; 172: 1595-1599; discussion 1599.
56. Malide D, Russo P, Bendayan M. Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum Pathol 1995; 26: 558-564.
57. Takemura T, Yoshioka K, Murakami K et al. Cellular localization of inflammatory cytokines in human glomerulonephritis. Virchows Arch1994; 424: 459-464.
58. Noronha IL, Kruger C, Andrassy K et al. In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis. Kidney Int1993; 43: 682-692.
59. Gruss HJ, Dower SK. The TNF ligand superfamily and its relevance for human diseases. Cytokines Mol Ther 1995; 1: 75-105.
60. MacEwan DJ. TNF ligands and receptors - a matter of life and death. Br J Pharmacol 2002; 135: 855-875.
61. Lewis M, Tartaglia LA, Lee A et al. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci USA1991; 88: 2830-2834.
62. Grell M, Douni E, Wajant H et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995; 83: 793-802.
63. Kafrouni MI, Brown GR, Thiele DL. The role of TNF-TNFR2 interactions in generation of CTL responses and clearance of hepatic adenovirus infection. J Leukoc Biol 2003; 74: 564-571.
64. Brown GR, Lee E, Thiele DL. TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class IIdisparate (C57BL/6J-C57BL/6J x bm12)F1 mice. J Immunol 2002; 168: 3065-3071.
65. Xu J, Chakrabarti AK, Tan JL et al. Essential role of the TNF-TNFR2 cognate interaction in mouse dendritic cell-natural killer cell crosstalk. Blood 2007; 109: 3333-3341.
66. Herbein G, Mahlknecht U, Batliwalla F et al. Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 1998; 395: 189-194.
67. Bradley JR, Thiru S, Pober JS. Disparate localization of 55-kd and 75-kd tumor necrosis factor receptors in human endothelial cells. Am J Pathol1995; 146: 27-32.
68. Jones SJ, Ledgerwood EC, Prins JB et al. TNF recruits TRADD to the plasma membrane but not the trans-Golgi network, the principal subcellular location of TNF-R1. J Immunol 1999; 162: 1042-1048.
69. Himeno T, Watanabe N, Yamauchi N et al. Expression of endogenous tumor necrosis factor as a protective protein against the cytotoxicity of exogenous tumor necrosis factor. Cancer Res 1990; 50: 4941-4945.
70. Vanhaesebroeck B, Decoster E, Van Ostade X et al. Expression of an exogenous tumor necrosis factor (TNF) gene in TNF-sensitive cell lines confers resistance to TNF-mediated cell lysis. J Immunol 1992; 148: 2785-2794.
71. Santee SM, Owen-Schaub LB. Human tumor necrosis factor receptor p75/80 (CD120b) gene structure and promoter characterization. J Biol Chem 1996; 271: 21151-21159.
72. Rothe J, Bluethmann H, Gentz R et al. Genomic organization and promoter function of the murine tumor necrosis factor receptor beta gene. Mol Immunol 1993; 30: 165-175.
73. Vandenabeele P, Declercq W, Beyaert R et al. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol 1995; 5: 392-399.
74. Kemper O, Wallach D. Cloning and partial characterization of the promoter for the human p55 tumor necrosis factor (TNF) receptor. Gene1993; 134: 209-216.
75. Vielhauer V, Stavrakis G, Mayadas TN. Renal cell-expressed TNF receptor 2, not receptor 1, is essential for the development of glomerulonephritis. J Clin Invest 2005; 115: 1199-1209.
76. Al-Lamki RS, Wang J, Vandenabeele P et al. TNFR1- and TNFR2-mediated signaling pathways in human kidney are cell type-specific and differentially contribute to renal injury. FASEB J 2005; 19: 1637-1645.
77. Ramesh G, Reeves WB. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 2003; 285: F610-F618.
78. Kollias G. TNF pathophysiology in murine models of chronic inflammation and autoimmunity. Semin Arthritis Rheum 2005; 34: 3-6.
79. Kontoyiannis D, Pasparakis M, Pizarro TT et al. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements. Implications for joint and gut-associated immunopathologies. Immunity1999; 10: 387-398.
80. Puga I, Lainez B, Fernandez-Real JM et al. A polymorphism in the 30 untranslated region of the gene for tumor necrosis factor receptor 2 modulates reporter gene expression. Endocrinology 2005; 146: 2210-2220.
81. Lainez B, Fernandez-Real JM, Romero X et al. Identification and characterization of a novel spliced variant that encodes human soluble tumor necrosis factor receptor 2. Int Immunol 2004; 16: 169-177.
82. Van Zee KJ, Kohno T, Fischer E et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89: 4845-4849.
83. Xanthoulea S, Pasparakis M, Kousteni S et al. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med 2004; 200: 367-376.
84. Diez-Ruiz A, Tilz GP, Zangerle R et al. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol 1995; 54: 1-8.
85. Samsonov MY, Tilz GP, Egorova O et al. Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus. Lupus 1995; 4: 29-32.
86. Karkar AM, Smith J, Pusey CD. Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumour necrosis factor-alpha. Nephrol Dial Transplant 2001; 16: 518-524.
87. Karkar AM, Tam FW, Steinkasserer A et al. Modulation of antibodymediated glomerular injury in vivo by IL-1ra, soluble IL-1 receptor, and soluble TNF receptor. Kidney Int 1995; 48: 1738-1746.
88. Galon J, Aksentijevich I, McDermott MF et al. TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol 2000; 12: 479-486.
89. Tartaglia LA, Ayres TM, Wong GH et al. A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993; 74: 845-853.
90. Plitz T, Huffstadt U, Endres R et al. The resistance against Listeria monocytogenes and the formation of germinal centers depend on a functional death domain of the 55 kDa tumor necrosis factor receptor. Eur J Immunol 1999; 29: 581-591.
91. Ermolaeva MA, Michallet MC, Papadopoulou N et al. Function of TRADD in tumor necrosis factor receptor 1 signaling and in TRIF-dependent inflammatory responses. Nat Immunol 2008; 9: 1037-1046.
92. Kelliher MA, Grimm S, Ishida Y et al. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 1998; 8: 297-303.
93. Rothe M, Sarma V, Dixit VM et al. TRAF2-mediated activation of NFkappa B by TNF receptor 2 and CD40. Science 1995; 269: 1424-1427.
94. Thommesen L, Laegreid A. Distinct differences between TNF receptor 1- and TNF receptor 2-mediated activation of NFkappaB. J Biochem Mol Biol 2005; 38: 281-289.
95. Zhou Z, Connell MC, MacEwan DJ. TNFR1-induced NF-kappaB, but not ERK, p38MAPK or JNK activation, mediates TNF-induced ICAM-1 and VCAM-1 expression on endothelial cells. Cell Signal 2007; 19: 1238-1248.
96. Grech AP, Gardam S, Chan T et al. Tumor necrosis factor receptor 2 (TNFR2) signaling is negatively regulated by a novel, carboxyl-terminal TNFR-associated factor 2 (TRAF2)-binding site. J Biol Chem 2005; 280: 31572-31581.
97. Depuydt B, van Loo G, Vandenabeele P et al. Induction of apoptosis by TNF receptor 2 in a T-cell hybridoma is FADD dependent and blocked by caspase-8 inhibitors. J Cell Sci 2005; 118: 497-504.
98. Goukassian DA, Qin G, Dolan C et al. Tumor necrosis factor-alpha receptor p75 is required in ischemia-induced neovascularization. Circulation 2007; 115: 752-762.
99. Luo D, Luo Y, He Y et al. Differential functions of tumor necrosis factor receptor 1 and 2 signaling in ischemia-mediated arteriogenesis and angiogenesis. Am J Pathol 2006; 169: 1886-1898.
100. Pan S, An P, Zhang R et al. Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis. Mol Cell Biol 2002; 22: 7512-7523.
101. Zhang R, Xu Y, Ekman N et al. Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway. J Biol Chem 2003; 278: 51267-51276.
102. Zanotti S, Kumar A, Kumar A. Cytokine modulation in sepsis and septic shock. Expert Opin Investig Drugs 2002; 11: 1061-1075.
103. Douni E, Kollias G. A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R. J Exp Med 1998; 188: 1343-1352.
104. Pober JS. Endothelial activation: intracellular signaling pathways. Arthritis Res 2002; 4(Suppl 3): S109-S116.
105. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev1990; 70: 427-451.
106. Olleros ML, Guler R, Corazza N et al. Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin-alpha. J Immunol 2002; 168: 3394-3401.
107. Alexopoulou L, Pasparakis M, Kollias G. A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling. Eur J Immunol 1997; 27: 2588-2592.
108. Edwards III CK, Bendele AM, Reznikov LI et al. Soluble human p55 and p75 tumor necrosis factor receptors reverse spontaneous arthritis in transgenic mice expressing transmembrane tumor necrosis factor alpha. Arthritis Rheum 2006; 54: 2872-2885.
109. Willuweit A, Sass G, Schoneberg A et al. Chronic inflammation and protection from acute hepatitis in transgenic mice expressing TNF in endothelial cells. J Immunol 2001; 167: 3944-3952.
110. Timoshanko JR, Sedgwick JD, Holdsworth SR et al. Intrinsic renal cells are the major source of tumor necrosis factor contributing to renal injury in murine crescentic glomerulonephritis. J Am Soc Nephrol 2003; 14: 1785-1793.
111. Kamanna VS, Pai R, Bassa B et al. Activation of mesangial cells with TNFalpha stimulates M-CSF gene expression and monocyte proliferation: evidence for involvement of protein kinase C and protein tyrosine kinase. Biochim Biophys Acta 1996; 1313: 161-172.
112. Pai R, Ha H, Kirschenbaum MA et al. Role of tumor necrosis factor-alpha on mesangial cell MCP-1 expression and monocyte migration: mechanisms mediated by signal transduction. J Am Soc Nephrol 1996; 7: 914-923.
113. Radeke HH, Meier B, Topley N et al. Interleukin 1-alpha and tumor necrosis factor-alpha induce oxygen radical production in mesangial cells. Kidney Int 1990; 37: 767-775.
114. Wiggins RC, Njoku N, Sedor JR. Tissue factor production by cultured rat mesangial cells. Stimulation by TNF alpha and lipopolysaccharide. Kidney Int 1990; 37: 1281-1285.
115. Timoshanko JR, Tipping PG. Resident kidney cells and their involvement in glomerulonephritis. Curr Drug Targets Inflamm Allergy 2005; 4: 353-362.
116. Sheerin NS, Zhou W, Adler S et al. TNF-alpha regulation of C3 gene expression and protein biosynthesis in rat glomerular endothelial cells. Kidney Int 1997; 51: 703-710.
117. Sheerin NS, Springall T, Carroll MC et al. Protection against antiglomerular basement membrane (GBM)-mediated nephritis in C3- and C4-deficient mice. Clin Exp Immunol 1997; 110: 403-409.
118. Hebert MJ, Takano T, Papayianni A et al. Acute nephrotoxic serum nephritis in complement knockout mice: relative roles of the classical and alternate pathways in neutrophil recruitment and proteinuria. Nephrol Dial Transplant 1998; 13: 2799-2803.
119. Pasparakis M, Alexopoulou L, Episkopou V et al. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 1996; 184: 1397-1411.
120. Matsumoto M, Fu YX, Molina H et al. Lymphotoxin-alpha-deficient and TNF receptor-I-deficient mice define developmental and functional characteristics of germinal centers. Immunol Rev 1997; 156: 137-144.
121. Liu J, Marino MW, Wong G et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 1998; 4: 78-83.
122. Eugster HP, Frei K, Bachmann R et al. Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1. Eur J Immunol1999; 29: 626-632.
123. Suvannavejh GC, Lee HO, Padilla J et al. Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG(35-55)- induced experimental autoimmune encephalomyelitis. Cell Immunol2000; 205: 24-33.
124. Kassiotis G, Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med 2001; 193: 427-434.
125. Jacob CO, Aiso S, Michie SA et al. Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-alpha and interleukin 1. Proc Natl Acad Sci USA 1990; 87: 968-972.
126. Chan KF, Siegel MR, Lenardo JM. Signaling by the TNF receptor superfamily and T cell homeostasis. Immunity 2000; 13: 419-422.
127. Zheng L, Fisher G, Miller RE et al. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995; 377: 348-351.
128. Cusson N, Oikemus S, Kilpatrick ED et al. The death domain kinase RIP protects thymocytes from tumor necrosis factor receptor type 2- induced cell death. J Exp Med 2002; 196: 15-26.
129. Pimentel-Muinos FX, Seed B. Regulated commitment of TNF receptor signaling: a molecular switch for death or activation. Immunity 1999; 11: 783-793.
130. Speiser DE, Sebzda E, Ohteki T et al. Tumor necrosis factor receptor p55 mediates deletion of peripheral cytotoxic T lymphocytes in vivo. Eur J Immunol 1996; 26: 3055-3060.
131. Zhou T, Edwards III CK, Yang P et al. Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor I. J Immunol 1996; 156: 2661-2665.
132. Grewal IS, Grewal KD, Wong FS et al. Local expression of transgene encoded TNF alpha in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T cells. J Exp Med 1996; 184: 1963-1974.
133. McSorley SJ, Soldera S, Malherbe L et al. Immunological tolerance to a pancreatic antigen as a result of local expression of TNFalpha by islet beta cells. Immunity 1997; 7: 401-409.
134. Cope AP, Liblau RS, Yang XD et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 1997; 185: 1573-1584.
135. Isomaki P, Panesar M, Annenkov A et al. Prolonged exposure of T cells to TNF down-regulates TCR zeta and expression of the TCR/CD3 complex at the cell surface. J Immunol 2001; 166: 5495-5507.
136. Lens SM, Tesselaar K, den Drijver BF et al. A dual role for both CD40- ligand and TNF-alpha in controlling human B cell death. J Immunol 1996; 156: 507-514.
137. Botto M, Dell'Agnola C, Bygrave AE et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998; 19: 56-59.
138. Paul E, Carroll MC. SAP-less chromatin triggers systemic lupus erythematosus. Nat Med 1999; 5: 607-608.
139. Bickerstaff MC, Botto M, Hutchinson WL et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999; 5: 694-697.
140. Ozen S, Saatci U, Tinaztepe K et al. Urinary tumor necrosis factor levels in primary glomerulopathies. Nephron 1994; 66: 291-294.
141. Tomosugi NI, Cashman SJ, Hay H et al. Modulation of antibodymediated glomerular injury in vivo by bacterial lipopolysaccharide, tumor necrosis factor, and IL-1. J Immunol 1989; 142: 3083-3090.
142. Chen YM, Ng YY, Lin SL et al. Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats. Nephrol Dial Transplant 2004; 19: 1106-1115.
143. Karkar AM, Koshino Y, Cashman SJ et al. Passive immunization against tumour necrosis factor-alpha (TNF-alpha) and IL-1 beta protects from LPS enhancing glomerular injury in nephrotoxic nephritis in rats. Clin Exp Immunol 1992; 90: 312-318.
144. Khan SB, Cook HT, Bhangal G et al. Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int 2005; 67: 1812-1820.
145. Le Hir M, Haas C, Marino M et al. Prevention of crescentic glomerulonephritis induced by anti-glomerular membrane antibody in tumor necrosis factor-deficient mice. Lab Invest 1998; 78: 1625-1631.
146. Ryffel B, Eugster H, Haas C et al. Failure to induce anti-glomerular basement membrane glomerulonephritis in TNF alpha/beta deficient mice. Int J Exp Pathol 1998; 79: 453-460.
147. Jacobs M, Brown N, Allie N et al. Tumor necrosis factor receptor 2 plays a minor role for mycobacterial immunity. Pathobiology 2000; 68: 68-75.
148. Boyce NW, Holdsworth SR. Evidence for direct renal injury as a consequence of glomerular complement activation. J Immunol 1986; 136: 2421-2425.
149. Quigg RJ. Role of complement and complement regulatory proteins in glomerulonephritis. Springer Semin Immunopathol 2003; 24: 395-410.
150. Rosenkranz AR, Mendrick DL, Cotran RS et al. P-selectin deficiency exacerbates experimental glomerulonephritis: a protective role for endothelial P-selectin in inflammation. J Clin Invest 1999; 103: 649-659.
151. Kollias G, Kontoyiannis D. Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev 2002; 13: 315-321.
152. Tsuchiya N, Kawasaki A, Tsao BP et al. Analysis of the association of HLADRB1, TNFalpha promoter and TNFR2 (TNFRSF1B) polymorphisms with SLE using transmission disequilibrium test. Genes Immun 2001; 2: 317-322.
153. Jacob CO, Fronek Z, Lewis GD et al. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 1990; 87: 1233-1237.
154. Lee YH, Harley JB, Nath SK. Meta-analysis of TNF-alpha promoter -308 A/G polymorphism and SLE susceptibility. Eur J Hum Genet 2006; 14: 364-371.
155. Horiuchi T, Kiyohara C, Tsukamoto H et al. A functional M196R polymorphism of tumour necrosis factor receptor type 2 is associated with systemic lupus erythematosus: a case-control study and a metaanalysis. Ann Rheum Dis 2007; 66: 320-324.
156. Till A, Rosenstiel P, Krippner-Heidenreich A et al. The Met-196-Arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-alpha-induced apoptosis by impaired NF-kappaB signaling and target gene expression. J Biol Chem 2005; 280: 5994-6004.
157. Morita C, Horiuchi T, Tsukamoto H et al. Association of tumor necrosis factor receptor type II polymorphism 196R with Systemic lupus erythematosus in the Japanese: molecular and functional analysis. Arthritis Rheum 2001; 44: 2819-2827.
158. Tsuchiya N, Komata T, Matsushita M et al. New single nucleotide polymorphisms in the coding region of human TNFR2: association with systemic lupus erythematosus. Genes Immun 2000; 1: 501-503.
159. Chadha S, Miller K, Farwell L et al. Haplotype analysis of tumour necrosis factor receptor genes in 1p36: no evidence for association with systemic lupus erythematosus. Eur J Hum Genet 2006; 14: 69-78.
160. Boswell JM, Yui MA, Burt DW et al. Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis. J Immunol 1988; 141: 3050-3054.
161. Brennan DC, Yui MA, Wuthrich RP et al. Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. J Immunol 1989; 143: 3470-3475.
162. Yokoyama H, Kreft B, Kelley VR. Biphasic increase in circulating and renal TNF-alpha in MRL-lpr mice with differing regulatory mechanisms. Kidney Int 1995; 47: 122-130.
163. Herrera-Esparza R, Barbosa-Cisneros O, Villalobos-Hurtado R et al. Renal expression of IL-6 and TNFalpha genes in lupus nephritis. Lupus 1998; 7: 154-158.
164. Studnicka-Benke A, Steiner G, Petera P et al. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996; 35: 1067-1074.
165. Gabay C, Cakir N, Moral F et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997; 24: 303-308.
166. Maury CP, Teppo AM. Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum 1989; 32: 146-150.
167. Jacob CO, Lewis GD, McDevitt HO. MHC class II-associated variation in the production of tumor necrosis factor in mice and humans: relevance to the pathogenesis of autoimmune diseases. Immunol Res 1991; 10: 156-168.
168. Segal R, Dayan M, Zinger H et al. Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti- TNFalpha monoclonal antibody and by pentoxiphylline. Lupus 2001; 10: 23-31.
169. Deguchi Y, Kishimoto S. Tumour necrosis factor/cachectin plays a key role in autoimmune pulmonary inflammation in lupus-prone mice. Clin Exp Immunol 1991; 85: 392-395.
170. Edwards III CK, Zhou T, Zhang J et al. Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRLlpr/ lpr mice by a transcriptional inhibitor of TNF-alpha. J Immunol 1996; 157: 1758-1772.
171. Aringer M, Graninger WB, Steiner G et al. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an
172. Aringer M. A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNF-Alpha Chimeric Monoclonal Antibody (Infliximab) and Azathioprine in Patients Suffering From Systemic Lupus Erythematosus (SLE) With WHO Class V Glomerulonephritis (NCT00368264)http://www.clinicaltrials.gov, 2006.
173. Deguchi Y, Shibata N, Kishimoto S. Enhanced expression of the tumour necrosis factor/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis. Clin Exp Immunol 1990; 81: 311-314.
174. Hasegawa M, Nishii C, Kabutan N et al. Effects of cytapheresis on tumor necrosis factor receptor and on expression of CD63 in myeloperoxidase - antineutrophil cytoplasmic autoantibody-associated vasculitis. Ther Apher Dial 2007; 11: 337-340.
175. Spriewald BM, Witzke O, Wassmuth R et al. Distinct tumour necrosis factor alpha, interferon gamma, interleukin 10, and cytotoxic T cell antigen 4 gene polymorphisms in disease occurrence and end stage renal disease in Wegener's granulomatosis. Ann Rheum Dis 2005; 64: 457-461.
176. Kettritz R, Schreiber A, Luft FC et al. Role of mitogen-activated protein kinases in activation of human neutrophils by antineutrophil cytoplasmic antibodies. J Am Soc Nephrol 2001; 12: 37-46.
177. Rarok AA, Limburg PC, Kallenberg CG. Neutrophil-activating potential of antineutrophil cytoplasm autoantibodies. J Leukoc Biol 2003; 74: 3-15.
178. Little MA, Bhangal G, Smyth CL et al. Therapeutic effect of anti-TNFalpha antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J Am Soc Nephrol 2006; 17: 160-169.
179. Little MA, Smyth CL, Yadav R et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 2005; 106: 2050-2058.
180. Xiao H, Heeringa P, Hu P et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110: 955-963.
181. Huugen D, Xiao H, van Esch A et al. Aggravation of antimyeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol2005; 167: 47-58.
182. Pascher A, Klupp J. Biologics in the treatment of transplant rejection and ischemia/reperfusion injury: new applications for TNFalpha inhibitors? BioDrugs 2005; 19: 211-231.
183. Gasser M, Waaga-Gasser AM, Kist-van Holthe JE et al. Chronic rejection: insights from a novel immunosuppressive-free model of kidney transplantation. J Am Soc Nephrol 2004; 15: 687-694.
184. Herrero-Fresneda I, Franquesa M, Torras J et al. Role of cold ischemia in acute rejection: characterization of a humoral-like acute rejection in experimental renal transplantation. Transplant Proc 2005; 37: 3712-3715.
185. Noronha IL, Hartley B, Cameron JS et al. Detection of IL-1 beta and TNFalpha message and protein in renal allograft biopsies. Transplantation1993; 56: 1026-1029.
186. Hribova P, Kotsch K, Brabcova I et al. Cytokines and chemokine gene expression in human kidney transplantation. Transplant Proc 2005; 37: 760-763.
187. Oliveira SG, Oliveira IB, Abensur H et al. Differential expression of cytokines, growth factors, and alpha-smooth muscle actin in renal allograft biopsies. Transplant Proc 2002; 34: 479-481.
188. McLaughlin PJ, Aikawa A, Davies HM et al. Evaluation of sequential plasma and urinary tumor necrosis factor alpha levels in renal allograft recipients. Transplantation 1991; 51: 1225-1229.
189. Dorge SE, Roux-Lombard P, Dayer JM et al. Plasma levels of tumor necrosis factor (TNF) and soluble TNF receptors in kidney transplant recipients. Transplantation 1994; 58: 1000-1008.
190. Oliveira JG, Xavier P, Sampaio SM et al. sTNFRI and sTNFRII synthesis by fine-needle aspiration biopsy sample cultures is significantly associated with acute rejection in kidney transplantation. Transplantation 2001; 71: 1835-1839.
191. Wiggins MC, Bracher M, Mall A et al. Tumour necrosis factor levels during acute rejection and acute tubular necrosis in renal transplant recipients. Transpl Immunol 2000; 8: 211-215.
192. Zegarska J, Paczek L, Pawlowska M et al. Quantitative gene expression of TGF-beta1, TNF-alpha, IL-1beta, and IL-6 in the renal artery wall of chronically rejected human renal allografts. Transplant Proc 2002; 34: 3176-3179.
193. Suzuki J, Cole SE, Batirel S et al. Tumor necrosis factor receptor-1 and -2 double deficiency reduces graft arterial disease in murine cardiac allografts. Am J Transplant 2003; 3: 968-976.
194. Eason JD, Wee S, Kawai T et al. Inhibition of the effects of TNF in renal allograft recipients using recombinant human dimeric tumor necrosis factor receptors. Transplantation 1995; 59: 300-305.
195. Wilson AG, Symons JA, McDowell TL et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94: 3195-3199.
196. Alakulppi NS, Kyllonen LE, Jantti VT et al. Cytokine gene polymorphisms and risks of acute rejection and delayed graft function after kidney transplantation. Transplantation 2004; 78: 1422-1428.
197. Park JY, Park MH, Park H et al. TNF-alpha and TGF-beta1 gene polymorphisms and renal allograft rejection in Koreans. Tissue Antigens2004; 64: 660-666.
198. Tinckam K, Rush D, Hutchinson I et al. The relative importance of cytokine gene polymorphisms in the development of early and late acute rejection and six-month renal allograft pathology. Transplantation2005; 79: 836-841.
199. Poli F, Boschiero L, Giannoni F et al. Tumour necrosis factor-alpha gene polymorphism: implications in kidney transplantation. Cytokine 2000; 12: 1778-1783.
200. Sankaran D, Asderakis A, Ashraf S et al. Cytokine gene polymorphisms predict acute graft rejection following renal transplantation. Kidney Int1999; 56: 281-288.
201. Pelletier R, Pravica V, Perrey C et al. Evidence for a genetic predisposition towards acute rejection after kidney and simultaneous kidney-pancreas transplantation. Transplantation 2000; 70: 674-680.
202. Pawlik A, Domanski L, Rozanski J et al. IL-2 and TNF-alpha promoter polymorphisms in patients with acute kidney graft rejection. Transplant Proc 2005; 37: 2041-2043.
203. Hahn AB, Kasten-Jolly JC, Constantino DM et al. TNF-alpha, IL-6, IFNgamma, and IL-10 gene expression polymorphisms and the IL-4 receptor alpha-chain variant Q576R: effects on renal allograft outcome. Transplantation 2001; 72: 660-665.
204. Wramner LG, Norrby J, Hahn-Zoric M et al. Impaired kidney graft survival is associated with the TNF-alpha genotype. Transplantation 2004; 78: 117-121.
205. Dmitrienko S, Hoar DI, Balshaw R et al. Immune response gene polymorphisms in renal transplant recipients. Transplantation 2005; 80: 1773-1782.
206. Nikolova PN, Ivanova MI, Mihailova SM et al. Cytokine gene polymorphism in kidney transplantation - impact of TGF-beta 1, TNF-alpha and IL-6 on graft outcome. Transpl Immunol 2008; 18: 344-348.
207. Melk A, Henne T, Kollmar T et al. Cytokine single nucleotide polymorphisms and intrarenal gene expression in chronic allograft nephropathy in children. Kidney Int 2003; 64: 314-320.
208. Pawlik A, Domanski L, Rozanski J et al. The cytokine gene polymorphisms in patients with chronic kidney graft rejection. Transpl Immunol 2005; 14: 49-52.
209. Manchanda PK, Mittal RD. Analysis of cytokine gene polymorphisms in recipient's matched with living donors on acute rejection after renal transplantation. Mol Cell Biochem 2008; 311: 57-65.
210. Haraoui B. Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum 2005; 34: 7-11.
211. Lugering A, Schmidt M, Lugering N et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001; 121: 1145-1157.
212. Reimold AM. New indications for treatment of chronic inflammation by TNF-alpha blockade. Am J Med Sci 2003; 325: 75-92.
213. Sandborn WJ, Hanauer SB, Katz S et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088-1094.
214. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-1035.
215. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-333; quiz 591.
216. Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J Rheumatol Suppl 2002; 65: 33-38.
217. Brown SL, Greene MH, Gershon SK et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 3151-3158.
218. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50: 1740-1751.
219. Stone JH, Holbrook JT, Marriott MA et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2006; 54: 1608-1618.
220. Askling J, Fored CM, Baecklund E et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1414-1420.
221. Guillevin L. Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides With Positive ANCA After Relapse or Resistant Immunosuppressant Therapies (NCT00307593)http:// www.clinicaltrials.gov, 2004.
222. Haridas V, Darnay BG, Natarajan K et al. Overexpression of the p80 TNF receptor leads to TNF-dependent apoptosis, nuclear factor-kappa B activation, and c-Jun kinase activation. J Immunol 1998; 160: 3152-3162.